PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAtezolizumab
Tecentriq(atezolizumab)
Tecentriq (atezolizumab) is an antibody pharmaceutical. Atezolizumab was first approved as Tecentriq on 2016-05-18. It is used to treat alveolar soft part sarcoma, hepatocellular carcinoma, melanoma, non-small-cell lung carcinoma, and small cell lung carcinoma amongst others in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, and urologic neoplasms. The pharmaceutical is active against programmed cell death 1 ligand 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Tecentriq
Combinations
Tecentriq hybreza
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Atezolizumab
Tradename
Proper name
Company
Number
Date
Products
TecentriqatezolizumabGenentechN-761034 RX2016-05-18
2 products
Atezolizumab
+
Hyaluronidase
Tradename
Proper name
Company
Number
Date
Products
Tecentriq Hybrezaatezolizumab and hyaluronidase-tqjsGenentechN-761347 RX2024-09-12
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
tecentriqBiologic Licensing Application2025-11-25
tecentriq hybrezaBiologic Licensing Application2025-12-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
hepatocellular carcinoma—D006528C22.0
urinary bladder neoplasms—D001749C67
melanoma—D008545—
small cell lung carcinoma—D055752—
alveolar soft part sarcoma—D018234—
extravasation of diagnostic and therapeutic materials—D005119—
Agency Specific
FDA
EMA
Expiration
Code
atezolizumab, Tecentriq, Genentech, Inc.
2029-12-09Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF05: Atezolizumab
HCPCS
Code
Description
J9022
Injection, atezolizumab, 10 mg
Clinical
Clinical Trials
1651 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——13820463248382
NeoplasmsD009369—C8019914915326305
Lung neoplasmsD008175—C34.907311821246221
Hepatocellular carcinomaD006528—C22.0379320253182
Liver neoplasmsD008113EFO_1001513C22.0377917342159
MelanomaD008545——60556114111
Lung diseasesD008171EFO_0003818J98.4—41117
PneumoniaD011014EFO_0003106J18———123
Interstitial lung diseasesD017563EFO_0004244J84.9———123
OncogenesD009857———1—1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.05011512—41189
Breast neoplasmsD001943EFO_0003869C50607114—10127
Small cell lung carcinomaD055752——345513—18100
Colorectal neoplasmsD015179——41497—386
Triple negative breast neoplasmsD064726——394713—485
Neoplasm metastasisD009362EFO_0009708—43398—574
Squamous cell carcinoma of head and neckD000077195——40426—471
Renal cell carcinomaD002292EFO_0000376—38335—467
Squamous cell carcinomaD002294——27424—259
Urinary bladder neoplasmsD001749—C67213310—358
Show 66 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509——1420——127
Squamous cell neoplasmsD018307——1015——223
Non-hodgkin lymphomaD008228—C85.9168———17
GlioblastomaD005909EFO_0000515—1013———16
Cutaneous malignant melanomaD000096142——99———13
LeukemiaD007938—C9597——112
Skin neoplasmsD012878EFO_0004198C4477——112
Neuroendocrine tumorsD018358EFO_1001901D3A.859——112
Follicular lymphomaD008224—C8268———10
Pancreatic ductal carcinomaD021441——56———10
Show 122 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Disease progressionD018450——1———23
Bites and stingsD001733——2————2
FibrosarcomaD005354——1————1
Malignant fibrous histiocytomaD051677——1————1
DermatofibrosarcomaD018223——1————1
Large-cell lymphoma anaplasticD017728—C84.61————1
PlasmacytomaD010954—C90.31————1
Hematologic diseasesD006402EFO_0005803D75.91————1
Bone marrow diseasesD001855——1————1
MeaslesD008457—B051————1
Show 19 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249MP_0001845—————44
MyocarditisD009205—I51.4————33
Heart diseasesD006331EFO_0003777I51.9————22
MicrobiotaD064307——————22
MetagenomeD054892——————22
MyositisD009220EFO_0000783G72.49————22
Drug-related side effects and adverse reactionsD064420—T88.7————22
Autoimmune diseasesD001327EFO_0000540M30-M36————22
Cardiovascular diseasesD002318EFO_0000319I98————11
CardiomyopathiesD009202EFO_0000318I42————11
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAtezolizumab
INNatezolizumab
Description
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma. It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>5XXY:H|heavy chain of atezolizumab fab EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTMDPGGSHHHHHHHH >5XXY:L|light chain of atezolizumab fab DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5X8L, 5XXY
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3707227
ChEBI ID—
PubChem CID—
DrugBankDB11595
UNII ID52CMI0WC3Y (ChemIDplus, GSRS)
Target
Agency Approved
CD274
CD274
Organism
Homo sapiens
Gene name
CD274
Gene synonyms
B7H1, PDCD1L1, PDCD1LG1, PDL1
NCBI Gene ID
29126
Protein name
programmed cell death 1 ligand 1
Protein synonyms
B7 homolog 1, B7-H1, CD274, CD274 antigen, PDCD1 ligand 1
Uniprot ID
Q9NZQ7
Mouse ortholog
Cd274 (60533)
programmed cell death 1 ligand 1 (Q9EP73)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Tecentriq – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 42,103 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
32,673 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use